Medication for alcohol use disorder refers to FDA-approved drugs that lower cravings, blunt alcohol’s rewarding effects, or create unpleasant reactions when alcohol is consumed. Here at Porch Light Health, we know that asking about these medications is rarely a casual question. It usually comes after months or years of trying to cut back, broken promises to yourself, and a quiet hope that something might finally make this easier.
This page walks through how those medications work, what dosing typically looks like, and the safety checks that keep treatment on track. It supports a real conversation with a clinician, not a replacement for one.
Medication for alcohol use disorder, often called MAT for alcohol, refers to FDA-approved or off-label drugs used alongside counseling. These medicines work best when paired with psychosocial treatment, and the right one depends on your medical history, treatment goals, and any contraindications.
Many adults with moderate to severe alcohol use disorder who want to cut back or stop drinking may benefit from medication paired with counseling. The National Institute on Alcohol Abuse and Alcoholism reports that millions of U.S. adults need treatment in any given year, and most never receive it, a treatment gap our network is built to close.
The goal is rarely to “cure” alcohol use disorder. Realistic goals include:
A thoughtful plan keeps treatment practical and close to home, which makes it easier to stick with.
The FDA has approved three medications for alcohol use disorder:
SAMHSA lists these as the primary pharmacologic options, with the choice depending on treatment goals, medical history, and adherence patterns.
Oral naltrexone blocks opioid receptors in the brain, which reduces the rewarding effects of alcohol and lowers cravings. We typically consider naltrexone therapy when the goal is to cut heavy drinking or reduce relapse risk.
The monthly injection delivers steady opioid receptor blockade and removes the need to remember a daily pill, which can improve adherence. Our team can walk through how Vivitrol compares to other injectable options if you are weighing both.
Acamprosate helps restore the glutamate and GABA balance disrupted by chronic alcohol use. It is mainly used to support sustained abstinence after detox, and it works best for people whose primary goal is staying alcohol-free.
Disulfiram inhibits aldehyde dehydrogenase, so drinking alcohol while taking it causes flushing, nausea, and a fast heart rate. It works as a deterrent for highly motivated patients and is most effective when dosing is supervised, either by a family member or a clinic.
Each medication targets a different biological pathway, which is why matching the medication to your goals matters more than picking the “best” drug.
A systematic review in JAMA summarized 118 trials and found oral naltrexone (50 mg/day) and acamprosate effective for the outcomes that matter most to patients: fewer heavy drinking days and more abstinent days. A 2022 network meta-analysis ranked acamprosate, naltrexone, and baclofen among the top agents.
| Medication | Primary Effect | Best When Your Goal Is | Common Dose |
| Oral Naltrexone | Reduces cravings and heavy drinking | Cutting back without full abstinence | 50 mg once daily |
| Injectable Naltrexone (Vivitrol) | Same as oral, with monthly dosing | Adherence is hard with daily pills | 380 mg IM every 4 weeks |
| Acamprosate | Stabilizes brain chemistry after detox | Maintaining abstinence post-withdrawal | 666 mg three times daily |
| Disulfiram (Antabuse) | Causes unpleasant reaction if you drink | Strong deterrent with supervised dosing | 250–500 mg daily |
| Topiramate (Off-Label) | Reduces heavy drinking | First-line options unsuitable | Titrated, 100–300 mg/day |
| Gabapentin (Off-Label) | Reduces drinking and helps sleep | Co-occurring anxiety or insomnia | 600–1,800 mg/day |
Match the medication to your goal first, then talk dosing and interactions through with your prescriber, and plan how you will monitor for side effects. If craving reduction is the part you are most curious about, our deeper write-up on whether MAT helps alcohol cravings walks through what to expect in the first weeks.
The table below summarizes the standard adult dosing for each FDA-approved medication.
| Medication | Route | Typical Adult Dose | Frequency |
| Oral Naltrexone | Oral tablet | 50 mg | Once daily |
| Naltrexone (Vivitrol) | Intramuscular injection | 380 mg | Every 4 weeks |
| Acamprosate | Oral tablet | 666 mg (≈ 2 g/day) | Three times daily |
| Disulfiram | Oral tablet | 250–500 mg | Once daily |
Oral medications should be taken according to label guidance with respect to food. Injectable naltrexone is given in the gluteal muscle every 4 weeks, and adherence is reviewed at each follow-up visit. Acamprosate dosing is adjusted for kidney function, and insurance prior authorization for injectables is best confirmed before the first appointment.
Injectable formulations carry a higher list price than oral medications and often require prior authorization or step therapy. Our team checks formulary tiers before prescribing and coordinates with your insurance to prevent coverage delays.
Every medication for alcohol use disorder carries specific safety considerations. Knowing what to watch for is part of safe treatment, not a reason to avoid it. Our team coordinates medication monitoring and follow-up across our clinics in Colorado and New Mexico.
The most common side effects and safety considerations by medication are summarized below. We cover what patients tend to notice first in our naltrexone side effects write-up.
| Medication | Most Common Side Effects | Key Safety Check | Hard Contraindication |
| Naltrexone (Oral or Injectable) | Nausea, headache, fatigue | Baseline + periodic LFTs | Active opioid use, severe liver disease |
| Disulfiram | Drowsiness, metallic taste | Confirm sobriety before starting | Severe heart disease, psychosis |
| Acamprosate | Diarrhea, drowsiness | Renal function (eGFR) | eGFR < 30 mL/min/1.73 m² |
| Topiramate (Off-Label) | Cognitive slowing, paresthesias, weight loss | Cognition + mood monitoring | Pregnancy, glaucoma |
| Gabapentin / Pregabalin (Off-Label) | Sedation, dizziness | Misuse risk in SUD history | Caution with respiratory depression |
The disulfiram-alcohol reaction can be dangerous. Patients receive clear instructions on hidden alcohol sources (mouthwash, sauces, some medications) and confirm sobriety before starting.
Naltrexone should not be used with ongoing opioid therapy and should be held for 7 to 10 days after any depot opioid before initiation, per the FDA Vivitrol label.
Baseline and periodic liver tests are part of standard monitoring. Treatment is reassessed if transaminases climb significantly, if cognitive side effects are persistent, or if there are signs of misuse. When in doubt, your prescriber or pharmacist is the right person to ask before any new medication is added or stopped.
Starting medication for alcohol use disorder begins with targeted baseline tests, screening for pregnancy and recent opioid use, and early safety check-ins so any side effects are caught early. You can find a nearby clinic to start or continue care through our Find a Clinic tool.
Liver function tests and a pregnancy test are obtained for everyone before starting medication. Kidney function is checked before prescribing acamprosate. Hepatitis C screening is added for patients with risk factors.
If baseline liver tests are abnormal, they are rechecked within 1 to 2 weeks of starting naltrexone. We also monitor adherence, side effects, and urine toxicology as clinically indicated.
A phone check during the first week is used to assess tolerance, followed by an in-person visit at one month and routine reviews every three months with labs as needed.
Before starting medication, our intake team confirms:
Patients are counseled to avoid opioids while on naltrexone and to watch for jaundice, severe rash, or new suicidal thoughts, any of which warrant urgent evaluation. If labs worsen, side effects become intolerable, or heavy drinking continues despite adherence, we either switch medications or step up to a higher level of care.
A clear monitoring plan is what keeps medication safe while it has time to work. Our team handles the scheduling and labs so you can focus on your recovery rather than the logistics.
Off-label medications can be useful when the FDA-approved options are not a good fit. Evidence supports modest benefit for some agents, and they tend to work best within a comprehensive treatment plan rather than as standalone solutions.
Topiramate and gabapentin have produced moderate reductions in heavy drinking in randomized trials. Baclofen and nalmefene show smaller, less consistent benefits across populations.
Major addiction medicine and hepatology guidelines treat these medications as off-label or conditional options. Clinicians typically prioritize FDA-approved medications first and reserve these agents for selected patients after a careful informed-consent conversation.
Routine use is avoided in pregnancy and in adolescents. Early pharmacogenetic findings, such as GRIK1 variants and topiramate response, are promising but are not yet ready for routine clinical use.
These agents are used cautiously, with documented informed consent about off-label status and risks, and with monitoring for cognition, sedation, and signs of misuse. For complex cases, we coordinate with addiction specialists or refer.
Picking a medication is a shared decision. Your treatment goal, medical history, prior medication response, and practical factors like cost and access all shape the choice.
If your goal is to reduce heavy drinking, naltrexone is often a strong first step. If abstinence is the target, acamprosate is frequently the right fit. The clearer you can be about what you want, the more tailored the plan can be.
Be sure to mention liver disease, current or recent opioid use, bipolar disorder, and pregnancy plans. These conditions can change which medications are safe and effective, and we coordinate dual diagnosis treatment for clients with co-occurring mental health diagnoses.
We talk through benefits, side effects, dosing schedule, and insurance coverage. Baseline labs and a pregnancy check are arranged, and an early follow-up is scheduled to confirm tolerance and adherence so we can adjust the plan if needed.
For most patients, an initial course of 6 to 12 months is a reasonable starting plan, with regular reassessments along the way. Our network supports ongoing care across clinics, mobile sites, and telemedicine, which makes it easier to stay engaged through the long-tail of recovery.
Six to twelve months is a common initial course, after which the plan is reassessed based on drinking reduction, side effects, adherence, and your goals. National guidelines support an individualized duration with periodic review.
Tapering happens under clinical supervision so we can monitor for withdrawal and adverse effects. The taper speed is matched to the medication’s half-life and your stability. For some medications, a slower taper reduces symptom rebound.
A clear relapse-action plan is part of every treatment record. If a relapse happens, we may restart, switch, or combine medications and increase counseling and peer support. We refer to specialty addiction care when relapses are repeated or comorbidities are complex.
Medication is most effective when it is paired with counseling, peer support, and connection to community resources. Our behavioral health team handles this side of the plan and meets clients where they are, in person or via telemedicine.
Starting medication for alcohol use disorder usually follows the same general workflow, whether you are seen in-clinic or via telemedicine:
Careful documentation and early follow-up help us catch safety issues quickly and decide when specialty addiction care is the right next step.
Pharmacotherapy for alcohol use disorder remains underused despite clear benefits. Community-delivered care lowers transportation and stigma barriers, and community-level strategies are effective for reducing excessive alcohol use.
Our network expands access through clinics, mobile addiction treatment units, and telemedicine to meet you where you are. You can find a nearby location or virtual option by calling 866-394-6123. Treatment closer to home is treatment that is easier to keep.
Which medications are first-line for alcohol use disorder and why?
Naltrexone and acamprosate are typically first-line because randomized trials and clinical guidelines show they reduce heavy drinking days and increase abstinent days when paired with psychosocial support. Naltrexone is associated with reductions in heavy drinking, and acamprosate is associated with sustained abstinence.
The right choice depends on your goal, comorbidities, and whether daily or monthly dosing fits your life.
Can I take naltrexone if I am on opioid pain medications or buprenorphine?
No. Naltrexone is not started in patients currently taking opioid agonists because it can precipitate severe opioid withdrawal. Recent opioid use must be confirmed absent before initiation.
If you are stable on buprenorphine or methadone for opioid use disorder, the usual approach is to continue that therapy and use alternative AUD strategies, often coordinated through specialty care, rather than starting naltrexone right away.
How long before I see benefits, and can I stop once I feel better?
Many people notice fewer cravings and fewer heavy drinking days within 2 to 4 weeks of starting naltrexone. Acamprosate may take several weeks to clearly support abstinence. Individual response varies based on adherence and the supports around the medication.
Stopping medication just because you feel better tends to raise relapse risk. Guidelines commonly recommend continuing pharmacotherapy for at least 6 to 12 months and then making an individualized decision with your clinician about tapering or stopping.
Are anticonvulsants like topiramate or gabapentin safe and effective?
Topiramate and gabapentin have evidence for reducing heavy drinking, but they are off-label for alcohol use disorder and carry important safety considerations. Topiramate showed clinically meaningful reductions in drinking in randomized trials but can cause cognitive slowing and paresthesias. Gabapentin can reduce drinking in some trials but has misuse potential in populations with a substance use history.
These agents are typically used when first-line options are unsuitable, with documented informed consent and monitoring for cognitive side effects, mood changes, and signs of misuse.
What labs do I need before starting naltrexone or acamprosate, and how often?
Liver function tests are checked at baseline before naltrexone, and kidney function is checked before acamprosate, since acamprosate dosing is renally adjusted. After starting naltrexone, LFTs are typically rechecked within 1 to 3 months and then periodically based on your clinical status.
Naltrexone is held if LFTs run more than three times the upper limit of normal until values improve. Acamprosate is avoided or dose-adjusted when estimated glomerular filtration rate falls below 30 mL/min per 1.73 m².
Is the injectable naltrexone more effective than the oral version?
Extended-release injectable naltrexone improves real-world adherence by replacing daily pills with a monthly visit. Head-to-head randomized comparisons do not show a large efficacy difference across all outcomes, so the choice depends on patient preference, adherence barriers, and cost.
For people whose routines are unstable or who have struggled to take a daily pill, the injectable often improves treatment persistence in everyday life.
What if a patient drinks while taking disulfiram or has an adverse reaction?
A disulfiram-alcohol reaction warrants medical attention. Mild reactions include flushing, headache, and nausea. Severe reactions can involve very low blood pressure, chest pain, or breathing difficulty and need emergency evaluation.
If drinking happens without a severe reaction, the focus shifts to safety planning, identifying triggers, and deciding with your clinician whether disulfiram is still the right medication.
How do clinicians overcome insurance and access barriers?
Coverage limits are addressed with accurate coding, peer-to-peer appeals, and generics where appropriate. For injectables, documenting a trial of oral therapy and medical necessity supports prior authorization.
Telemedicine, local clinic partnerships, and patient navigators expand access. Our team helps patients enroll in assistance programs and schedule injections so cost rarely becomes the deciding factor.
Whether you’re asking about medication for alcohol use disorder for yourself or for someone you love, our team at Porch Light Health is here, not to judge, but to help. A confidential call takes about five minutes and can answer what you’re wondering about next steps, insurance, and what treatment actually looks like.
Call our admissions team at 866-394-6123 to speak with someone today, or find a clinic near you to start with a location.
Same-day consultations are often available. We’re here when you’re ready.
